Source:http://linkedlifedata.com/resource/pubmed/id/16040722
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2005-11-14
|
pubmed:abstractText |
Recent data suggest that beta-adrenergic receptor subtypes couple differentially to signaling pathways regulating cardiac function vs. cardiac remodeling. To dissect the roles of beta1- vs. beta2-receptors in the pathogenesis of cardiomyopathy, doxorubicin was administered to beta1, beta2, and beta1/beta2 knockout (-/-) and wild-type mice. Expression and activation of MAPKs were measured. Wild-type and beta1-/- mice showed no acute cardiovascular effects, whereas beta2-/- mice all died within 30 min. The additional deletion of the beta1-receptor (beta1/beta2-/-) totally rescued this toxicity. beta2-/- mice developed decreased contractile function, hypotension, QTc prolongation, and ST segment changes and a 20-fold increase in p38 MAPK activity not seen in the other genotypes. The MAPK inhibitor SB-203580 rescued beta2-/- mice from this acute toxicity. The enhanced toxicity in beta2-/- mice was also recapitulated in wild-type mice with the beta2-selective antagonist ICI-118,551, although the rescue effect of the beta1-deletion was not recapitulated using the beta1-selective antagonist metoprolol or the nonselective beta-antagonist propranolol. These data suggest that beta2-adrenergic receptors play a cardioprotective role in the pathogenesis of cardiomyopathy, whereas beta1-adrenergic receptors mediate at least some of the acute cardiotoxicity of anthracyclines. Differential activation of MAPK isoforms, previously shown in vitro to regulate beta-agonist as well as doxorubicin cardiotoxicity, appears to play a role in mediating the differential effects of these beta-adrenergic receptor subtypes in vivo.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0363-6135
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
289
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
H2441-9
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:16040722-Animals,
pubmed-meshheading:16040722-Blood Pressure,
pubmed-meshheading:16040722-Cardiomyopathy, Dilated,
pubmed-meshheading:16040722-Cardiotonic Agents,
pubmed-meshheading:16040722-Heart Rate,
pubmed-meshheading:16040722-Mice,
pubmed-meshheading:16040722-Mice, Knockout,
pubmed-meshheading:16040722-Receptors, Adrenergic, beta-1,
pubmed-meshheading:16040722-Receptors, Adrenergic, beta-2,
pubmed-meshheading:16040722-Survival Rate
|
pubmed:year |
2005
|
pubmed:articleTitle |
Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes.
|
pubmed:affiliation |
Dept. of Pediatrics, 750 Welch Rd., Suite 305, Palo Alto, CA 94304, USA. danb@stanford.edu
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|